Pancreatic cancer (PC) is largely refractory to existing therapies used in unselected patient trials, thus emphasizing the pressing need for new approaches for patient selection in personalized medicine. KRAS mutations occur in 90% of PC patients and confer resistance to epidermal growth factor receptor (EGFR) inhibitors (e.g., panitumumab), suggesting that KRAS wild-type PC patients may benefit from targeted panitumumab therapy. Here, we use tumor tissue procured by endoscopic ultrasound-guided fine-needle aspirate (EUS-FNA) to compare the in vivo sensitivity in patient-derived xenografts (PDXs) of KRAS wild-type and mutant PC tumors to panitumumab, and to profile the molecular signature of these tumors in patients with metastatic or localized disease. Specifically, RNASeq of EUS-FNA-derived tumor RNA from localized (n 5 20) and metastatic (n 5 20) PC cases revealed a comparable transcriptome profile. Screening the KRAS mutation status of tumor genomic DNA obtained from EUS-FNAs stratified PC patients into either KRAS wild-type or mutant cohorts, and the engraftment of representative KRAS wild-type and mutant EUS-FNA tumor samples into NOD/SCID mice revealed that the growth of KRAS wild-type, but not mutant, PDXs was selectively suppressed with panitumumab. Furthermore, in silico transcriptome interrogation of The Cancer Genome Atlas (TCGA)-derived KRAS wild-type (n 5 38) and mutant (n 5 132) PC tumors revealed 391 differentially expressed genes. Taken together, our study validates EUS-FNA for the application of a novel translational pipeline comprising KRAS mutation screening and PDXs, applicable to all PC patients, to evaluate personalized anti-EGFR therapy in patients with KRAS wild-type tumors.
can cause potential complications including pancreatitis, bleeding, infection and perforation, 3 these are quite infrequent (0.3-2.2%), and its accuracy of 85% compares favourably with other biopsy techniques, 2 thus ideally placing it to provide material for the genetic characterization of PC. While EUS-FNA has been used to provide tissue for genetic analysis of PC, the clinical utility of this information has been limited largely due to low tissue quantities leading to suboptimal yields of genetic material, and sample contamination with non-malignant cells. 4 Nonetheless, the inherent advantage of EUS-FNA is the ability to sample tumors from patients who are ineligible for surgical resection, which in the context of PC is 80%, thus providing clinicians the ability to obtain tissue which would otherwise be unavailable. 5 Recent advances in next-generation sequencing (NGS) technologies have enhanced our understanding of the high degree of inter-tumoral heterogeneity among PC patients. For instance, genome-wide association studies on large cohorts (>5,000) of PC patients and control individuals have identified numerous PC susceptibility loci containing genes which have previously been implicated in oncogenesis (e.g., BCAR1, KLF14, PDX1, TERT). 6 More recently, whole-exome sequencing of resected tumor tissue from a smaller cohort of 109 PC patients reported that 5% of cases contained 24 significantly mutated genes, some of which not only provided prognostic value in terms of disease pathology or patient survival (e.g., KRAS, RBM10), but also identified patients who may respond to targeted therapies (e.g., BRAF, PIK3CA). 7 Notably, the high genetic diversity of PC tumors provides a rational explanation for the relatively slow progress in the development of novel and effective chemotherapies for PC, especially since all new treatments have previously been evaluated on unselected PC patient populations. [8] [9] [10] [11] [12] Accordingly, personalized therapeutic approaches based on the genetic profile of individual tumors in PC provide the opportunity to vastly improve patient outcomes. 8, 9 In PC, KRAS mutations are of particular interest because they are observed in 90% of patients, and based on other cancers such as non-small cell lung cancer and colorectal cancer, the mutation status of KRAS may predict responsiveness to epidermal growth factor receptor (EGFR) inhibitors. [13] [14] [15] A major obstacle to personalized therapy for PC has been the difficulty in isolating high quality tumor-derived genetic material (genomic DNA and/or RNA) in sufficient quantities for subsequent molecular profiling. Indeed, this has been recently reported by the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial which was designed to identify subsets of patients with advanced metastatic disease who could be targeted, based on mutations within their tumor genome, with currently-available therapies. 9 An additional limitation of the IMPaCT study was the heavy reliance upon tissue primarily from archival formalin-fixed, paraffin-embedded (FFPE) samples for genomic DNA extraction, most of which were derived from surgical resections which are possible in only 20% of PC patients presenting with localized disease. 9 Accordingly, there is an urgent and unmet clinical need to improve methodologies for the robust isolation of high quality genetic material in a timely manner from the vast majority of PC patients. Here, we systematically address current issues with tumor sampling, as well as specimen collection and processing, and demonstrate that EUS-FNA can be a reliable source of high quality genetic material for the molecular profiling of both localized and metastatic PC. Moreover, transcriptome profiling of EUS-FNA, along with interrogation of TCGA datasets (from surgical resection), for PC identified potentially targetable phenotypes for localized and metastatic disease, as evidenced by the responsiveness of KRAS wild-type tumors from an EUS-FNA-derived PDX model to the EGFR inhibitor, panitumumab. Collectively, our findings pave the way for future studies aimed at both improving our understanding of advanced (i.e., metastatic) PC, and also generating molecular profiles to stratify patients for personalized treatment regimens.
Material and Methods
Human specimen collection PC samples were collected from patients undergoing EUS-FNA for investigation of a pancreatic mass at Monash Health (MH) Victoria, Australia. For each patient, initial diagnostic aspirates from the pancreatic mass were collected using 22-Gauge procore needles (Cook Medical) with 10 ml of suction for immediate cytological assessment. After confirmation of cellular quantity, an additional aspirate was taken from the same position and snap-frozen in liquid nitrogen. Normal pancreas was obtained by surgical resection, performed at MH, for conditions other than PC. Duodenum and stomach
What's new?
While pancreatic cancer is a genetically heterogeneous disease, 90% of patients exhibit mutations in KRAS. Most patients also respond poorly to generalized treatments, suggesting that patient outcomes may depend on genetic profiling and personalized therapeutic approaches. A potential role for those approaches was explored here, using tumor tissue procured from patients via endoscopic ultrasound-guided fine-needle aspirate (EUS-FNA). Patient-derived xenografts were developed and screened for KRAS mutation status and sensitivity to panitumumab. Only KRAS wild-type EUS-FNA patient-derived xenografts were sensitive to the drug. Genetic profiling coupled with EUS-FNA, an existing clinical tool, is suited for rapid translation into clinical trials.
tissues were obtained from patients without PC by routine endoscopic biopsy and snap-frozen. All tissue samples were stored at 2808C.
Whole blood was collected from healthy volunteers in EDTA-coated tubes (Becton Dickinson and Company).
Written and informed patient consent was obtained for each procedure, with approval from MH and Monash University Human Research Ethics Committees (approval number 13058A).
RNA and genomic DNA extraction
Total RNA and genomic DNA (gDNA) were simultaneously extracted from snap-frozen EUS-FNA samples by homogenization in Buffer RLT Plus (Qiagen AllPrep DNA/RNA Universal Kit) as per the manufacturer's protocol. Isolation of gDNA from formalin-fixed, paraffin-embedded (FFPE) tissue was performed on 5 3 10 lm-thick sections using the ReliaPrep FFPE gDNA Miniprep System (Promega). The quality and quantity of gDNA and RNA were determined using the Nanodrop Spectrophotometer (ThermoScientific), and Qubit Fluorometer (Life Technologies).
Gene expression analyses
cDNA was synthesized from 0.5 lg RNA using SuperScript III (Invitrogen), and subsequent real-time quantitative polymerase chain reaction (qPCR) was performed using the 7900HT Fast RT-PCR system (Applied Biosystems). The expression of target genes was normalized relative to 18S rRNA, and data acquisition and analyses were performed using the Sequence Detection System Version 2.4 software (Applied Biosystems). Sequences of human gene forward and reverse primers are listed in Supporting Information Transcriptome panel primers were designed. After alignment, the ampliSeqRNA plugin examined the number of reads mapping to the expected amplicon ranges and assigned counts per gene for reads which align to these regions as defined in the BED file (hg19_ AmpliSeq_Transcriptome_21K_v1.bed). Reads aligning to the expected amplicon locations were referred to as "on target" reads and were reported as a percentage of total reads by the plugin.
Gene mutation analyses
gDNA (25-50 ng) was subjected to the KRAS-BRAF Strip Assay (ViennaLab Diagnostics GmbH), and mutations were objectively scored using Strip Assay Evaluator software.
Identification and selection of treatable PC phenotypes
Electronic searches were performed using Ovid Medline, Pubmed and Embase to identify potentially treatable PC phenotypes by combining the terms "pancreatic adenocarcinoma," "molecularly targeted therapy" and "chemotherapy." All retrieved articles were reviewed to compile a list of all mutations targetable with currently available treatments. The incidence of each of these phenotypes in PC was then obtained by analysis of the OMICS database.
In silico analyses
Transcriptome analysis of our EUS-FNA samples and TCGA data sets (http://cancergenome.nih.gov/) was performed using R packages: DEseq2, Bioconductor and Limma for quality control, normalization and differential gene expression analysis. Clinical data and mutation status from DNASeq datasets were compiled and analyzed by contrasting the transcriptome profile, histological and clinical information for tumors with or without KRAS and DNA-repair pathway mutations (BRCA1/2, PALB2 and ATM) from TCGA data sets.
Cytology and histological analyses
Cytological evaluation was performed on Diff-Quik stained and air-dried slides, Papanicolaou-stained and wet-fixed smears. EUS-FNA cell block preparations were made using clotted needle cores which were placed in a fine mesh cassette and then into a regular cassette for processing in histology, thus mimicking a mini biopsy for diagnostic staining.
Immunohistochemistry EUS-FNA cell block sections were used for immunohistochemical staining with antibodies against Cytokeratin 7 (Dako), Cytokeratin 19 (Ventana Medical Systems/Roche) and CD45 (Ventana Medical Systems, Inc./Roche). Slides were stained using the Ventana BenchMark ULTRA Automated IHC slide staining system (Roche), and the Ventana ultraView Universal DAB Detection kit (Roche) with amplification step was used for visualization of the staining reaction. Hematoxylin was used as the counterstain. EUS-FNA PDX tumor sections were stained with antibodies against pan-Cytokeratin (Santa Cruz), CD45 (BD BioSciences), Human Nuclei (Merck-Millipore), Proliferating Cell Nuclear Antigen (PCNA, Cell Signaling Technologies), and the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Merck-Millipore). The Avidin/Biotin complex formation kit ABC Vectastain (Vector Labs), and DAB chromogen (Biocare Medical) staining, were also used. Sections were counterstained with Hematoxylin. Staining was quantified by counting positive cells per 20 high-powered fields (HPF).
Western blotting
Protein lysates from PDX tumors were prepared by homogenizing tumor tissue pieces in 1 mL of lysis buffer (50 mM Tris, 150 mM NaCl, 1% (v/v) Trition X-100, 1 mM EDTA, (v/v) NaF, 1% (v/v) NaVO4, 1% (v/v) and 1 tablet of protease inhibitor (EDTA-free)). Lysates were examined by Western blot with primary antibodies against total and phosphorylated (p) EGFR (R&D Systems), total and pAKT (Cell Signaling Technologies), total and pERK1/2 (Santa Cruz, and Cell Signaling Technologies), and a-tubulin (Abcam). Membranes were exposed to IRDye V R Secondary Antibodies diluted in Odyssey V R Blocking Buffer, and then scanned on an Odyssey fluorimager (LI-COR) infrared imaging system.
Patient-derived xenografts
EUS-FNA samples were collected in saline, finely minced, washed and re-suspended in ice-cold 150 ll Dulbecco's Modified Eagles Media (DMEM) and 150 ll Matrigel (Corning Life Sciences). Samples were implanted into each of 2 female NOD/SCID mice (Animal Resource Centre, Western Australia) using a subcuticular injection (150 lL). Tumors grew for 3-6 months to a maximum volume of 1,000 mm 3 , at which point tumors were excised for subsequent passaging (up to 4 times prior to expansion in experimental treatment cohorts). To passage, tumors from "donor" mice were minced into 2 mm pieces and then coated in Matrigel, followed by implantation into a subcuticular pocket on the flank of a female NOD/SCID mouse.
For experimental treatment cohorts, female NOD/SCID mice were randomized into one of four treatment groups (n 5 4 mice/group): saline (0.2 mL intraperitoneal (i.p.) injection twice weekly), panitumumab alone (Amgen; 200 lg, i.p. twice weekly), gemcitabine alone (Accord; 50 mg/kg i.p. twice weekly), and a combination of panitumumab and gemcitabine. Mice were administered with reagents once grafted tumors were established and reached a volume of 100 mm All experiments were performed on mice housed in a specific pathogen-free environment with approval from the Monash University Animal Ethics Committee (MMCA 2015/08).
Statistical analyses
Statistical analysis was performed using GraphPad Prism for Windows version 5.0, and where appropriate parametric (oneway ANOVA) or nonparametric (Kruskal-Wallis, MannWhitney) tests were used. For clinical characteristics, v 2 d or Fischer exact tests were used to compare groups of patients from TCGA datasets based on phenotype. p < 0.05 was considered to be statistically significant. Data are expressed as the mean 6 standard error of the mean (SEM).
Results
Optimization of genomic DNA and total RNA extraction from EUS-FNA samples
The potential of EUS-FNA for personalizing cancer therapy is dependent on the quality and quantity of genetic material that can be isolated from EUS-FNA-acquired biopsies. We therefore optimized the isolation of PC tumor gDNA and RNA by trialling a variety of strategies from 66 EUS-FNA samples (Supporting Information Fig. 1a) . Ultimately, we demonstrated that maximal yields were obtained from one EUS-FNA pass when snap-frozen in liquid nitrogen, and then homogenized and divided into smaller aliquots prior to processing (Supporting Information Figs. 1b21d) . Using this strategy, both RNA and DNA were simultaneously isolated with an average yield of 12.9 6 3.2 lg and 4.8 6 3.7 lg, respectively (Method 3; Supporting Information Figs. 1b and 1d). Yields of gDNA were approximately 10-fold higher when an additional EUS-FNA pass was performed, thus demonstrating utility in overcoming sampling deficiencies.
High epithelial cell content of PC EUS-FNA-derived samples
As previous studies utilizing EUS-FNA biopsies have documented issues with suboptimal content of tumor (i.e., epithelial) cells, as well as contamination with non-malignant cells, 9 we investigated the cellular content of EUS-FNA-derived PC specimens. Histopathological examination of H&E-stained EUS-FNA PC biopsy sections revealed a mix of malignant epithelial, benign epithelial and immune/inflammatory cells (Fig. 1a) . The high epithelial content of EUS-FNA samples was verified by immunostaining for Cytokeratin 7 and 19, demonstrating pronounced numbers of cells positive for either marker throughout EUS-FNA-derived PC sections (Figs. 1b and 1c) . In contrast, very few CD45-positive immune cells were observed in PC sections (Fig. 1d) .
We further assessed the epithelial (i.e., tumor cell) content of EUS-FNA samples by performing qPCR to compare the expression levels of target genes representative of epithelial and immune (blood) cells, as well as pancreatic, gastric and duodenal tissue, in EUS-FNA-derived RNA selected from 20 PC patients (Supporting Information Table 2 ). The latter two tissue types were chosen since FNA needles pass through either the gastric or duodenal mucosa when sampling the pancreas, and may therefore contain "contaminating" cells from these tissues. Gene expression of the epithelial cell markers Cytokeratin (KRT) 7 and 19 was equal or higher in RNA extracted from PC EUS-FNAs compared to normal pancreatic tissue collected by either resection or EUS-FNA, as well as gastric, duodenal and whole blood samples, thus confirming the high epithelial content of PC EUS-FNAs (Figs. 1e and 1f) . In contrast, mRNAs for cell markers of the duodenum (Villin; VIL1) and stomach (ATPase, H1/K1 exchanging, alpha polypeptide; ATP4A) were detected at low levels in both EUS-FNA-derived PC and normal pancreas (Figs. 1g and 1h) . We also observed that expression levels of Table 4 ) with heat map (j) and volcano plot (k) demonstrating the number of significantly, differentially expressed genes. In (k), black data points represent genes not significantly, differentially expressed between the two groups (Norm Resect and PC), and red data points represent genes that achieve significance in terms of gene expression levels between two groups (p < 0.05, |Log 2 FC|>1). Statistical significance was assessed using one-way ANOVA for panels e-i, and using in-built statistical tests within the R package Bioconductor to adjust for false-discovery rates for panel k.
the leukocyte (immune) cell marker CD45 were among the lowest in EUS-FNA-derived PC samples, with highest expression levels observed in whole blood samples (as expected) and surprisingly, in resected normal pancreas (Fig. 1I) .
To confirm the presence of malignant cells in EUS-FNA samples, we used mutated KRAS as a specific marker for PC. KRAS mutations were detected in 80% (16/20) of patients (Supporting Information Table 3 ). Notably, the KRAS mutation frequency in the same patients was significantly lower at 45% (9/20, p < 0.05) when using gDNA extracted from FFPE blocks (Supporting Information Table 3 ). We also observed in one of 20 PC patients, mutated KRAS in FFPE-derived DNA but not from EUS-FNA-derived DNA specimen. Despite this discrepancy, these data support the requirement for an additional EUS-FNA biopsy for DNA (and/or RNA) isolation in order to enhance sensitivity for KRAS mutation detection.
To demonstrate the utility of EUS-FNA-derived RNA for transcriptome profiling, we performed RNASeq on tumor samples from 40 PC patients, and on five normal pancreatic specimens. These analyses revealed 2,148 genes that were significantly, differentially expressed between the two groups (Figs. 1j and  1 k) . Importantly, the heat map (Fig. 1j ) demonstrated a higher degree of heterogeneity in tumor samples compared to the uniform gene expression seen in the five normal samples. Of note, 1/40 PC sample had a transcriptional profile that appeared typical of normal pancreas (Fig. 1j) . Since cytological diagnosis confirmed PC, and KRAS mutation was detected in the sample used for RNASeq, thus confirming the presence of malignant cells, we speculate that this specimen reflects inter-tumoral heterogeneity. 6 Collectively, these data indicate the successful procurement of tumor tissue by EUS-FNA with minimal contamination of immune and non-pancreatic epithelial cells. In addition, the high epithelial (tumor) cell content of EUS-FNA-derived PC suggests the suitability of EUS-FNA for both DNA and RNAbased molecular profiling in PC.
Genetic analysis and transcriptional profiling to guide treatment selection in PC
The greatest potential for the in-depth genetic analysis of EUS-FNA specimens lies in its ability to guide personalized treatment selection for virtually all PC patients. Review of the literature reveals that there are many potential treatable PC phenotypes (Table 1) , although some are of very low prevalence (e.g., PDGFR A/B mutations which occurs in <2%) and others depend upon the analysis of gene or protein expression levels for which the diagnostic threshold is not clearly defined (e.g., c-MET expression and the use of Cabozantinib). The five most prevalent and potentially treatable phenotypes of PC identified were; Localized PC treated with resection; KRAS wild-type treated with anti-EGFR inhibitors [13] [14] [15] ; DNA repair pathway mutations (BRCA1/2, ATM, PALB2) treated with DNA-damaging agents 16 ; HER2-amplification treated with trastuzumab 17, 18 ; and BRAF mutant PC treated with BRAF and MEK inhibitors 19, 20 (Table 1 and Supporting Information Fig. 2 ). Among these, resection for localized tumors remains the most effective treatment for PC. 5, 21 A fundamental unanswered question likely to have profound implications with respect to selection of patients for surgical resection is whether localized PC possesses a different molecular and genetic phenotype to metastatic PC. To address this question, we performed transcriptome profiling on EUS-FNA specimens from 20 localized and 20 metastatic PC by RNASeq (Supporting Information Table 4 ). Somewhat surprisingly, there was a marked homogeneity between the gene expression profiles of localized and metastatic tumors overall, with no significantly, differentially expressed genes 
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identified in the entire transcriptome of either disease stage (Figs. 2a and 2b ). These observations were also confirmed upon gene set enrichment analyses (GSEA), which indicated that no gene sets were significantly enriched (p < 0.01; false-discovery rate (FDR) q < 0.25). These results therefore suggest that despite wide inter-tumoral heterogeneity, the molecular (i.e., gene expression) profile of localized and metastatic PC tumors is comparable, thus providing a potential explanation for the poor outcomes of patients with localized disease after pancreatic resection.
To identify whether the mutational status of tumors for these potentially treatable PC phenotypes correlated with a specific molecular (i.e., gene expression) signature, we next performed in silico comparative analyses on matched TCGA genomic and transcriptomic datasets from 170 PC patients with localized disease (i.e., surgical resection specimens; Supporting Information Table 5 , (e) and (f), black data points represent genes not significantly differentially expressed between the two groups, and red data points represent genes that achieve significance in terms of gene expression levels between two groups (p < 0.05, |Log 2 FC| >1). Statistical significance was assessed using in-built statistical tests within the R package Bioconductor to adjust for false-discovery rates. Panels a and b refer to the RNASeq PC cohort (Supporting Information Table 4) , and c-f refer to TCGA cohort (Supporting Information Tables  5 and 7) . Fig. 2 ). We note that there was no copy number variant TCGA data available for HER2, which prevented assessment of HER2 amplification in PC patients. Also, the low number (4/170) of BRAF mutant tumors precluded any statistically-meaningful analysis of this treatable phenotype.
Supporting Information
Assessment of the transcriptome data for patients with KRAS wild-type tumors demonstrated clustering to one side of the hierarchical analysis heat map (Fig. 2c) . Also, differential gene expression analysis between KRAS wild-type and mutant tumors revealed 391 genes that achieved significance (p< 0.01, |Log 2 FC|>1; Figs. 2d and 2e) . Furthermore, comparing these transcriptome profiles against published gene sets using GSEA software revealed five gene sets (Computational gene sets, Cancer Modules 35, 110, 160, 184 and 221) that were significantly enriched in KRAS wild-type PC and two gene sets (miR-518 B/C and Kegg pathway glycosaminoglycan-biosynthesis) that were significantly enriched in KRAS mutant PC (Supporting Information Table 6 , Supporting Information Fig. 3 ; p < 0.01 and FDR q < 0.25). Conversely, the comparison of tumors with and without DNA repair pathway mutations (BRCA1/2, PALPB, ATM) indicated there was no clustering of cases nor any genes that were significantly, differentially expressed (Fig.  1f, and Supporting Information Fig. 2) .
Finally, we measured the frequencies of various clinicopathological disease criteria, including overall survival, disease stage and site of disease using Fischer-Exact or v 2 tests to compare the phenotypes of the KRAS wild-type and mutant PC, and to compare the phenotypes in presence or absence of DNA repair pathway mutations (BRCA1/2, PALPB, ATM). Among the criteria assessed, patients with KRAS mutant tumors were of a higher grade (p 5 0.0009) and have shorter survival (p 5 0.016) versus patients with wild-type KRAS (Fig. 3a, and Supporting Information Table 5 ). In contrast, there was no difference in the clinical phenotype based on the presence or absence of DNA repair mutations (Fig. 3b , and Supporting Information Table 7 ).
Collectively, these analyses suggest that among the treatable phenotypes in PC, KRAS wild-type tumors are the most prevalent and have the most distinctive transcriptome profile and clinical phenotype.
Establishment of PDX models for PC using EUS-FNA to evaluate the treatment responsiveness of KRAS wild-type versus mutant tumors
To evaluate the responsiveness of KRAS wild-type and mutant tumors to the anti-EGFR inhibitor panitumumab, we established a preclinical PDX model from two PC patients, one KRAS wild-type and the other KRAS mutant, using EUS-FNA tumor samples (Fig. 4a , and Supporting Information Table 8 ). We subsequently divided both PDX PC models into four different treatment cohorts: saline, gemcitabine alone (chosen as a representative first-line chemotherapy agent used in PC), panitumumab alone, and a combination of gemcitabine and panitumumab. The KRAS wild-type tumors treated with saline all grew to a maximum volume (1,000 mm 3 ) before the treatment course was completed, ranging from 14-21 days, with an average final tumor weight of 1.07 6 0.08 g. Notably, compared to saline-treated controls, KRAS wild-type tumors treated with panitumumab were significantly smaller in volume (Day 14, p < 0.05; Day 21, p < 0.0001) and final weight (0.19 6 0.05 g; p < 0.0001) over the 28 day experimental treatment period ( Figs. 4b and  4c) . Similarly, gemcitabine treatment also significantly impaired tumor growth compared to control saline-treated xenografts, however this anti-tumor activity was less pronounced compared to panitumumab (Day 14 and 21, p < 0.05; Day 28, p < 0.01). Combination therapy had similar effects on tumor growth as panitumumab monotherapy (Figs. 4b and 4c) .
Conversely, in KRAS mutant tumors, panitumumab alone had no effect on tumor growth, which was comparable to the unimpaired exponential growth seen in saline-treated xenografts (Figs. 4b and 4c ). Similar to KRAS wild-type tumors, gemcitabine 
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alone or in combination with panitumumab had a pronounced inhibitory effect on the growth rate of KRAS mutant tumors (Figs. 4b and 4c) , thus ruling out any synergistic effects between these drugs on PC tumors irrespective of their KRAS mutation status.
The differential responsiveness of PC KRAS wild-type and mutant tumors to panitumumab was associated with changes in tumor cell proliferation, since immunostaining with the cell proliferation marker PCNA was significantly reduced in panitumumab-treated KRAS wild-type, but not mutant, PC tumors compared to the corresponding saline-treated control xenografts (Figs. 5a and 5b) . In light of these observations, we next assessed the signalling pathways impacted by the preferential sensitivity of PC KRAS wild-type tumors to panitumumab by performing Western blots for proteins related to the EGFR pathway. As shown in Figures 5c and 5d , compared to saline treatment, panitumumab treatment alone resulted in reduced levels of phosphorylated (p) EGFR in both KRAS wild-type and mutant tumors, albeit only significant in the former, which further supports the mode of action of panitumumab to directly block the activation of the EGFR irrespective of the KRAS mutation status in PC. Interestingly, activation of the ERK1/2 MAPK pathway, which is associated with cellular proliferation, was significantly reduced only in KRAS wild-type tumors treated with panitumumab compared to saline (Figs. 5c and 5d) , which is consistent with the lower proliferative potential of these tumors (Figs. 5a and 5b) . By contrast, no changes were observed in the activation status of the cell survival pathway mediator, AKT (Figs. 5c and 5d) .
Collectively, these in vivo data demonstrate that panitumumab is a highly effective agent for the selective treatment of KRAS wild-type, but not mutant, tumors in PC. Furthermore, the reduced growth of these PC tumors to panitumumab is associated with the suppression of ERK MAPK signalling and tumor cell proliferation.
Discussion
It is becoming increasingly likely that future advances in PC therapy will rely on treatments tailored to each patient's individual tumor. In this respect, previous genetic characterization of PC has largely relied upon tissue obtained from resection specimens, which are only available in the minority of patients. Therefore, EUS-FNA could overcome this problem since it can be performed in virtually all PC patients. Here, we have sought to validate this by demonstrating the clinical potential for EUS-FNA to provide meaningful genetic information on nearly all patients with PC. EUS-FNA has been widely used to detect mutations in KRAS, 4 but we demonstrate that an additional biopsy is more effective than using FFPE cell blocks, which have been primarily used as the source of genetic material (i.e., genomic DNA) in the past. Therefore, we propose that the acquisition of an additional biopsy during the EUS-FNA procedure is necessary in order to reach sufficient sensitivity if we are to use mutational status of particular genes to direct therapy. In addition, as KRAS mutations are rarely seen in nonneoplastic, solid pancreatic lesions, 4, 8 the ability to detect KRAS mutations in EUS-FNA-derived DNA indicates that neoplastic tissue is present in sufficient quantities to obtain meaningful molecular information.
More recently, the transcriptome profile of EUS-FNAderived RNA for PC has been reported. 22 Our study used RNASeq to profile malignant and benign samples in order to generate a diagnostic gene signature, intended for lesions that cannot be diagnosed with cytology alone. However, the sensitivity and specificity of this approach did not improve on cytology alone, suggesting that it is unlikely to be applied in the clinic for diagnostic purposes. Another recent study used EUS-FNA-derived DNA from PC patients to compare the allelic frequency and mutation status of 160 cancer-related genes in EUS-FNA-derived and surgically-derived DNA. 23 In keeping with our findings, our study reported high concordance of mutation status results and similar allelic frequency between both sampling techniques. To further substantiate the tumoral component of EUS-FNA-derived genetic material we have shown here that there is a strong epithelial gene signature, and KRAS mutation is detectable in the majority of PC patients. Therefore, these findings support EUS-FNA as a viable technique for obtaining PC tumoral genetic material of sufficient quantity and quality for next-generation sequencing, and thus underpins the advancement of personalized medicine through identification of signatures comprising aberrantly-expressed and/or mutated genes in all PC patients.
Consistent with the known inter-tumoral heterogeneity of PC, 6 the transcriptome profile of 1/40 EUS-FNA-derived PC samples resembled that of normal pancreas, despite this sample being positive for mutant KRAS and cytological analysis verifying adenocarcinoma. Such an example of natural intertumoral heterogeneity is also supported by TCGA cohorts stratified into KRAS wild-type and mutant, where, for example, the transcription profile of KRAS wild-type tumors did not all cluster together (Fig. 2c) . Furthermore, the heat map (Fig. 2d ) reveals individual KRAS wild-type tumors with a gene expression pattern similar to that seen in KRAS mutant tumors (and vice versa).
Since genetic studies to date have largely focused on surgically-derived tissue, thus excluding the majority of patients who present with advanced metastatic disease, an advantage of our current study utilizing EUS-FNA is the ability to contrast the transcriptome profile of localized and metastatic PC. Surprisingly, no significant differences at the molecular level (i.e., gene expression) were identified between these two patient cohorts, therefore indicating that although patients with localized or metastatic disease have markedly different clinical phenotypes, at the molecular level they are remarkably comparable. Importantly, this finding is consistent with two previous studies that attempted to address this issue with a different approach involving patients who underwent pancreatic resection for their cancer and later acquired tissue Tumor Markers and Signatures from secondary lesions post-mortem. 24, 25 Transcriptome profiling of tumor samples and adjacent normal tissue has also been used to perform a "virtual microdissection," which demonstrated that the transcriptome profiles between primary and secondary sites of the same tumor are indeed very similar. 25 Also, a high mutational concordance between primary and secondary lesions has been reported. 24 Overall, these findings support our data and the notion that there is no molecular difference between metastatic or localized PC, and further suggest it is unlikely that a molecular biomarker for a localized tumor phenotype exists.
Another novel aspect of our current study was the use of TCGA to characterize the most prevalent treatable cancer phenotype, KRAS wild-type tumors, in PC, and thus build on previous studies demonstrating that KRAS wild-type acts as a biomarker for anti-EGFR treatment in colorectal and lung cancers. 13, [26] [27] [28] [29] Indeed, stratifying PC patients according to KRAS mutation status revealed, for the first time, large differences in the transcriptome profile. In addition, the differential gene expression profile of KRAS wild-type PC tumors corresponded to a different clinical phenotype, characterized by lower tumor grade and longer overall survival. Furthermore, using our PDX PC models derived from EUS-FNA samples, we demonstrate that KRAS wild-type tumors were sensitive to the EGFR inhibitor panitumumab, unlike KRAS mutant tumors, and the anti-tumor activity of panitumumab was associated with a lower proliferative index and ERK MAPK activation in treated tumors.
Interestingly, Moore, et al. 30 have previously shown in a trial of another anti-EGFR agent, erlotinib, on unselected patients that overall survival was increased. However, this difference was only 6.24 months compared to 5.91 months and therefore the treatment has not been widely adopted in clinical practice. It is possible that the relative ineffectiveness of this trial indicates that anti-EGFR therapies (such as erlotinib and panitumumab) need to be applied in a personalized approach, and will not work in all patients. A recent publication has presented data also suggesting that KRAS wild-type tumors are more responsive to panitumumab than KRAS mutant tumors in a PC PDX model. 31 Together with our current findings, this provides a strong argument for the use of EUS-FNA to stratify the KRAS status of PC for eligibility for panitumumab treatment, and therefore paves the way to replicate these findings in preclinical studies and subsequently in a clinical trial setting. In summary, we have shown that EUS-FNA can provide a useable source of genetic material to profile the genetic and molecular landscape of individual PC tumors, which in concert with matched PDXs can be used to evaluate the efficacy of personalized anti-cancer treatments. Such a translational pipeline provides the overwhelming majority of patients with PC the potential to participate in and benefit from both preclinical xenograft studies and clinical trials of personalized medicine in the future.
